Al-Sawaf, Othman, Cramer, Paula, Goede, Valentin, Hallek, Michael and Pflug, Natali (2017). Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review. Ther. Adv. Hematol., 8 (6). S. 197 - 206. LONDON: SAGE PUBLICATIONS LTD. ISSN 2040-6215

Full text not available from this repository.

Abstract

With a median age of 72 years at first diagnosis, chronic lymphocytic leukaemia (CLL) is a disease of the elderly. At this age, many patients cannot bear an intensive chemoimmunotherapy like fludarabine, cyclophosphamide and rituximab (FCR), and therapeutic decisions are commonly complicated by a high burden of accompanying comorbidities. Clinical trials, on the other hand, are mostly designed to include a far healthier and younger trial population, with a median age in most studies well below 70 years, leading to an insufficient reflection of clinical reality. With the introduction of new targeted therapies, treatment of CLL is currently undergoing a profound change. New compounds like ibrutinib or idelalisib have enlarged the therapeutic options in treating CLL. However, so far, these oral medications imply continuous intake by the patient, which will at some point lead to the issue of adherence in most patients. In addition, long-term experiences are largely missing. In this setting, one of the oldest chemoactive substances remains a viable option for many CLL patients and their treating physicians: bendamustine, a nitrogen-mustard derivative, has proven to be a safe and efficient agent for treatment of CLL in the first- and second-line setting. In particular, there is some evidence that the substance is relatively well tolerated in elderly and unfit patients. In this review, we summarize the current data on bendamustine in the treatment of elderly and unfit patients with CLL and aim to provide a concise analysis and outlook on the current and future role of this substance in the era of new targeted agents.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Al-Sawaf, OthmanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cramer, PaulaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goede, ValentinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hallek, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pflug, NataliUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-230393
DOI: 10.1177/2040620717699365
Journal or Publication Title: Ther. Adv. Hematol.
Volume: 8
Number: 6
Page Range: S. 197 - 206
Date: 2017
Publisher: SAGE PUBLICATIONS LTD
Place of Publication: LONDON
ISSN: 2040-6215
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
PREVIOUSLY UNTREATED PATIENTS; MULTICENTER PHASE-II; ELDERLY-PATIENTS; OPEN-LABEL; INITIAL THERAPY; TRIAL; RITUXIMAB; COMBINATION; CLL; CHLORAMBUCILMultiple languages
HematologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/23039

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item